Article Information
History
- November 5, 2024.
Article Versions
- You are currently viewing Version 1 of this article (November 5, 2024 - 14:07).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Alia Zander1,
- Rossin Erbe1,
- Yan Liu1,
- Ailin Jin1,
- Seung Won Hyun1,
- Sayantoni Mukhopadhyay1,
- Ben Terdich1,
- Mario Rosasco1,
- Nirali Patel1,
- Brett Mahon1,
- Kate Sasser1,
- Michelle Ting-Lin1,
- Halla Nimeiri1,
- Justin Guinney1,
- Douglas R. Adkins2,
- Matthew Zibelman3,
- Kyle A. Beauchamp1,
- Chithra Sangli1,
- Michelle M. Stein1,
- Timothy Taxter1,
- Timothy A. Chan4,
- Sandip Pravin Patel5 and
- Ezra Cohen1,5,*
- 1Tempus AI, Inc., Chicago, IL
- 2Division of Oncology, Washington University School of Medicine, St. Louis, MO
- 3Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA
- 4Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH
- 5Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA
- ↵*corresponding author; ezra.cohen{at}tempus.com
Posted November 05, 2024.
Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitors
